Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years.

Next Previous
Trial Profile

Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
  • Indications Influenza A virus H1N1 subtype
  • Focus Pharmacodynamics
  • Acronyms FLU-D-PAN-H1N1-021
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

Most Recent Events

  • 29 Dec 2010 Actual end date (1 Aug 2010) added as reported by ClinicalTrials.gov.
  • 29 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 22 Dec 2009 Preliminary results from an interim analysis of the seroconversion and seroprotection rates have been published in the journal Vaccines.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top